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This special issue gives an overview of the current
state-of-the-art of creating a bio-engineered pace-
maker. The subject has potential clinical interest. In-
deed, electronic pacemakers currently available have
several limitations, among which inadequate rate
adaptation to physiological needs, problems related to
the stimulating and sensing leads and infection of the
pacemaker pocket, which might be overcome by a bio-
pacemaker. Generation of a bio-pacemaker has also
scientiﬁc interest, because it may answer the long-
standing question of whether the complex structure of
the sinus node is indeed a prerequisite for reliable
pacemaking, or simpler structures might work as well.
Knowledge of normal pacemaker physiology pro-
vides the ground for the development of bio-pace-
makers. Various ionic currents contribute to sinoatrial
(SA) node pacemaking; moreover, the sinus node
comprises morphologically and functionally distinct
cell types, with different intrinsic rates and response to
autonomic agonists. As outlined by Opthof [11], these
differences are relevant to the width and stability of
autonomic modulation of sinus rate. The question may
be asked of whether such complexity, probably the
result of evolutionary adaptations, would also be re-
quired to create a bio-pacemaker. For reasons of
practicality, the strategies proposed thus far have
adopted a conservative ‘‘one channel’’ approach;
however, as genetic manipulation techniques improve,
reports of bio-pacemakers based on combinations of
mechanisms start appearing in the literature [3].
Current approaches to bio-pacemaker generation
have developed along two main lines. The ﬁrst aims to
induce pacemaker activity in normally quiescent
(‘‘working’’) myocardium. The second involves myo-
cardial implant of exogenous cells, engineered to sus-
tain pacemaker activity (‘‘cell-based’’ approach), once
electrically connected to the host myocardium.
Pacemaking can be induced in working myocardial
cells by modiﬁcation of their pattern of expression of
membrane currents. The required genetic modiﬁcation
is usually carried out by gene transfer to the site of
interest. This can be achieved theoretically by direct
transfection of a plasmid incorporating the gene, or by
infecting the tissue with a viral vector containing it. In
practical terms, only the viral infection provides ade-
quate transduction efﬁciency and is universally adop-
ted. Nonetheless, the infection procedure involves a
number of technical and safety problems. The repli-
cation-deﬁcient adenovirus is a safe and practical vec-
tor; however, because the gene is not incorporated into
the genome, its expression is only transient. Retrovi-
ruses, like the widely used lentivirus, incorporate the
added gene into the genome, which results in stable
gene expression. However, genomic transduction
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Such problems have prompted the development of
cell-based approaches, in which pacemaker function is
intrinsic to the implanted cell, or can be obtained
by genetic modiﬁcation prior to implant in the host
myocardium.
In the cell-based approach, several strategies have
been proposed. In one case spontaneously beating
clusters of myocytes derived from human embryonic
stem cells (hESCs) were directly used as pacemaker
elements [15]. However, once implanted, these cells
could further differentiate into quiescent elements,
thus compromising pacemaker stability. Another, more
promising, approach is based on in vitro genetic mod-
iﬁcation of exogenous cells, originally devoid of pace-
maker activity, which are stably transduced with a gene
encoding the current of interest. Once implanted, the
modiﬁed cells electrically couple to the surrounding
myocardium, and modulate its electrical activity [2, 12].
Cell-to-cell coupling is mediated by connexins, protein
channels that allow ionic current ﬂow between adja-
cent cells. Connexins are at hand in many cell-types,
including stem cells, which can successfully couple to
cardiac myocytes. Success of the cell-based approach
depends on the possibility of avoiding immunological
rejection of the implant; thus an autologous origin of
the implanted cells is highly desirable. Stem cells may
be particularly suitable for generating a bio-pacemaker
because they can be autologous and they replicate, thus
allowing ampliﬁcation of the cell population. An
alternative may be the development of replicating cell-
lines, engineered to achieve immunocompatibility.
To create a bio-pacemaker, the following strategies
are currently followed: (1) suppression of repolarizing
currents to unmask latent pacemaker currents in nor-
mally quiescent myocardial cells; (2) over-expression
of a pacemaker (depolarizing) current in electrically
quiescent cells to convert them into pace-making ele-
ments; (3) modulation of the expression of receptors
involved in the regulation of pacemaker currents [5].
The ﬁrst approach, a pioneering one in the ﬁeld of
bio-pacemakers, relies on the idea that ventricular
‘‘working’’ myocardium has latent pacemaker activity,
but spontaneous depolarization is normally suppressed
by a large repolarizing conductance, available at dia-
stolic potential. Such a conductance is provided by the
‘‘inward rectiﬁer’’ potassium current IK1, known for its
strong expression in electrically quiescent cells of the
atrial and ventricular working myocardium, but virtu-
ally absent from the AV and SA node. Therefore,
suppression of IK1 is a putative approach for creating a
bio-pacemaker. The group of Marban [9] provided a
proof of this concept by using a dominant-negative
Kir2.1 construct, packaged into an adenoviral vector.
Once infected with the vector in vivo, ventricular
myocardium showed 80% IK1 suppression and devel-
oped automatic activity [9]. Although conceptually
innovative, such an approach is encumbered by the
problems related to all viral transduction methods;
moreover, strict delimitation of the infection site is
difﬁcult and diffusion of IK1 suppression throughout
the ventricle may entail pro-arrhythmic risk.
With regard to over-expression of depolarizing
currents, much attention has been given to the main
depolarizing current that induces spontaneous activity
in the SA node, the funny current If, which is mediated
by a family of hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels. This area has been
pioneered by Rosen et al. [13], whose review in this
issue summarizes the evolution of the concept and the
results obtained. These authors used HCN2 as the If
encoding isoform because the resulting current kinetics
are more favorable than with HCN4 and its cAMP
responsiveness is greater than that of HCN1. These
investigators initially showed suitability of If over-
expression by injecting HCN2 encoding adenoviral
vectors into the left atrium or the left bundle branch of
intact dog hearts. Both injection sites proved to be
successful in generating an ectopic rhythm. In addition,
the experiments also proved that pacemaker activity
generated by expression of HCN2 was autonomically
regulated. To overcome the problems related to the
adenoviral infection method, the same group devel-
oped a cell-based approach. Human mesenchymal
stem cells (hMSC), loaded with the HCN2 gene, were
injected epicardially into the left ventricular free wall
and resulted into an idioventricular rhythm at the
injection site. This rhythm was signiﬁcantly faster than
the escape rhythm following AV nodal ablation, thus
providing efﬁcient pacemaker activity. Recent studies
also explored the feasibility to convert quiescent ven-
tricular myocytes into pacemakers using somatic cell
fusion [4, 8]. Chemically induced fusion between
myocytes and syngeneic ﬁbroblasts that had been
engineered to express pacemaker ion channels, has
been attempted. The advantage of this approach, with
respect to classical cell-based therapy, is that the gap-
junctional coupling between donor cells and host
myocardium, which might be sub-optimal or unstable
in time, is avoided.
Interestingly, a cell-based approach has also been
proposed as a mean to down-regulate heart rate. De
Boer et al. [2] reduced beating rate of spontaneously
active neonatal rat cardiomyocytes by co-culturing
them with IK1 overexpressing human embryonic
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These investigators also showed that the inﬂuence of
Kir2.1 expressing cells on beating rate could be less-
ened by the application of BaCl2, that blocks IK1. Since
pacemaker down-regulation occurred through elec-
tronic interaction between the two cell types, this result
also implies that efﬁcient connexin-mediated cell-to-
cell coupling spontaneously develops between HEK
cells and ventricular myocytes.
Recent evolutions in bio-pacemaking techniques
involve the expression of ‘‘synthetic’’ pacemaker
channels, obtained by modiﬁcation of genes originally
encoding non-pacemaker currents. The rationale of
this approach is the concern that co-assembly of added
HCN proteins with those naturally expressed by the
cell may result in unpredictable channel properties. To
generate a synthetic pacemaker channel, Kashiwakura
et al. [7] converted the depolarization-activated
potassium channel Kv1.4 into a hyperpolarization-
activated non-selective channel by 4-point-mutations.
The properties of the synthetic channel were similar to
those of HCN ones, but co-assembly between endog-
enous and added proteins was avoided.
A requirement for successful propagation of pace-
maker activity is an appropriate match between the
pacemaker generator properties and the electrical load
imposed by the tissue to be excited. Electrical-coupling
is required for propagation between pacemaker and
follower cells but, if the load is excessive, it may arrest
the pacemaker by clamping pacemaker cells to hy-
perpolarized resting membrane potentials. The SA
node has special means to circumvent this problem,
including expression of an hyperpolarization-activated
depolarizing current (If)[ 10] and a complex architec-
ture of the node-atrium interface [1, 6]. In the case of
bio-pacemakers, the interface architecture can be
hardly controlled; thus, for their development, predic-
tion of the interplay between polarizing and depolar-
izing currents and quantitative estimates of the
required generator size may be necessary. As reviewed
by Wilders in this issue [14], accurate computer models
of the SA node activity, now available, may help in
understanding how depolarizing and repolarizing cur-
rents interact and respond to perturbing conditions.
The problem of the match between generator and load
is illustrated in this issue by Joyner et al. [6]. These
investigators addressed this problem with a mixed ap-
proach in which SA electrical activity, generated by a
numerical model, was electrically coupled through a
variable resistor to a real atrial myocyte. This allowed
to test how coupling resistance may affect the pace-
maker-load interaction and to obtain a quantitative
evaluation of the conditions required for propagated
pacemaking [6].
As highlighted in this issue, research in the ﬁeld of
bio-pacemaking is blooming. Nonetheless, in light of
the performance and safety of the electronic pace-
makers now available, development of a better alter-
native is an extremely demanding task. It yet has to be
proven that the bio-pacemaker surpasses its electronic
counterpart with regard to adaptability to physiological
requirements of the body and longevity. While poten-
tially effective pacemaking strategies have been iden-
tiﬁed, the development of genetic engineering methods
suitable to implement them with safety and stability
remain a considerable challenge. The possibility of
uncontrolled gene expression, carcinogenic risk of
viral vectors affording stable transduction and
immune rejection of implants are among the problems
that need to be solved before bio-pacemaking can
be considered for clinical use. Moreover, ventricular
re-synchronization, a major advancement of artiﬁcial
pacemaking, may be difﬁcult to achieve with bio-
pacemakers.
Despite these concerns, bio-pacemaking seems more
easily achievable than other potential applications of
cardiac cell therapy. This is because bio-pacemaking
aims to restore a single function with a well-deﬁned
mechanism; it requires myocardial homing of a limited
number of cells and a localized intervention. Devel-
opment of bio-pacemakers may be an ideal challenge
for the approach typical of bioengineering, based on a
close interaction between expertise in biophysics,
molecular and cell biology.
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